BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37190813)

  • 21. Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents?
    Tebo C; Mazer-Amirshahi M; DeGeorge L; Gelfand B; Leak C; Tolliver S; Sauter D
    Am J Emerg Med; 2019 Oct; 37(10):1846-1849. PubMed ID: 30595429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthetic cannabinoid receptor agonists profile in infused papers seized in Brazilian prisons.
    Rodrigues TB; Souza MP; de Melo Barbosa L; de Carvalho Ponce J; Júnior LFN; Yonamine M; Costa JL
    Forensic Toxicol; 2022 Jan; 40(1):119-124. PubMed ID: 36454481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-Activity Relationships, Deuteration, and Fluorination of Synthetic Cannabinoid Receptor Agonists Related to AKB48, 5F-AKB-48, and AFUBIATA.
    Sparkes E; Maloney CJ; Markham JW; Dane C; Boyd R; Gilchrist J; Moir M; Gordon R; Luo JL; Pike E; Walker KA; Kassiou M; McGregor IS; Kevin RC; Hibbs DE; Jorgensen WT; Banister SD; Cairns EA; Ametovski A
    ACS Chem Neurosci; 2024 Jun; 15(11):2160-2181. PubMed ID: 38766866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacology, prevalence in Germany, and analytical data of cyclobutylmethyl- and norbornylmethyl-type synthetic cannabinoid receptor agonists.
    Pulver B; Riedel J; Schönberger T; Halter S; Lucas T; Opatz T; Grafinger KE; Scheu M; Zschiesche A; Pütz M; Pützer K; Westphal F; Auwärter V
    Drug Test Anal; 2023 Apr; 15(4):408-425. PubMed ID: 36541839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterizing Trends in Synthetic Cannabinoid Receptor Agonist Use from Patient Clinical Evaluations during Medical Toxicology Consultation.
    Tebo C; Mazer-Amirshahi M; Wax P; Campleman S; Boyer E; Brent J; Sheth A; Daniuaityte R; Carlson R
    J Psychoactive Drugs; 2021; 53(3):207-214. PubMed ID: 33225872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of Australian legislative changes on synthetic cannabinoid exposures reported to the New South Wales Poisons Information Centre.
    Cairns R; Brown JA; Gunja N; Buckley NA
    Int J Drug Policy; 2017 May; 43():74-82. PubMed ID: 28343112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using in vitro receptor activity studies of synthetic cannabinoids to support the risk assessment of new psychoactive substances - A Swedish strategy to protect public health from harm.
    Bäckberg M; Vikingsson S; Strandberg J; Wall S; Åstrand A; Karlsson H; Persson M; Kronstrand R; Green H
    Forensic Sci Int; 2023 Jul; 348():111691. PubMed ID: 37116244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of human T-type calcium channels by synthetic cannabinoid receptor agonists in vitro.
    Bladen C; Mirlohi S; Santiago M; Longworth M; Kassiou M; Banister S; Connor M
    Neuropharmacology; 2021 Apr; 187():108478. PubMed ID: 33600843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cannabinoid receptor activation potential of the next generation, generic ban evading OXIZID synthetic cannabinoid receptor agonists.
    Deventer MH; Van Uytfanghe K; Vinckier IMJ; Reniero F; Guillou C; Stove CP
    Drug Test Anal; 2022 Sep; 14(9):1565-1575. PubMed ID: 35560866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011-2014.
    Palamar JJ; Su MK; Hoffman RS
    Am J Drug Alcohol Abuse; 2016; 42(1):39-47. PubMed ID: 26678258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Large-scale evaluation of ion mobility spectrometry for the rapid detection of synthetic cannabinoid receptor agonists in infused papers in prisons.
    Norman C; McKirdy B; Walker G; Dugard P; NicDaéid N; McKenzie C
    Drug Test Anal; 2021 Mar; 13(3):644-663. PubMed ID: 33058556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Shape matters: The application of activity-based in vitro bioassays and chiral profiling to the pharmacological evaluation of synthetic cannabinoid receptor agonists in drug-infused papers seized in prisons.
    Antonides LH; Cannaert A; Norman C; NicDáeid N; Sutcliffe OB; Stove CP; McKenzie C
    Drug Test Anal; 2021 Mar; 13(3):628-643. PubMed ID: 33161649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does cannabis testing in the military drive synthetic cannabinoid use? Self-reported use motivations among justice-involved veterans.
    Santangelo O; Baldwin JM; Stogner J
    Int J Drug Policy; 2022 Aug; 106():103756. PubMed ID: 35738030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional evaluation of carboxy metabolites of synthetic cannabinoid receptor agonists featuring scaffolds based on L-valine or L-tert-leucine.
    Wouters E; Mogler L; Cannaert A; Auwärter V; Stove C
    Drug Test Anal; 2019 Aug; 11(8):1183-1191. PubMed ID: 31021521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthetic Cannabinoid-Related Deaths in England, 2012-2019.
    Yoganathan P; Claridge H; Chester L; Englund A; Kalk NJ; Copeland CS
    Cannabis Cannabinoid Res; 2022 Aug; 7(4):516-525. PubMed ID: 33998886
    [No Abstract]   [Full Text] [Related]  

  • 36. A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: Comparing prison and general populations.
    Norman C; Halter S; Haschimi B; Acreman D; Smith J; Krotulski AJ; Mohr ALA; Logan BK; NicDaéid N; Auwärter V; McKenzie C
    Drug Test Anal; 2021 Apr; 13(4):841-852. PubMed ID: 33463894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis.
    Craft S; Ferris JA; Barratt MJ; Maier LJ; Lynskey MT; Winstock AR; Freeman TP
    Psychopharmacology (Berl); 2022 May; 239(5):1349-1357. PubMed ID: 34533608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA.
    Banister SD; Adams A; Kevin RC; Macdonald C; Glass M; Boyd R; Connor M; McGregor IS; Havel CM; Bright SJ; Vilamala MV; Lladanosa CG; Barratt MJ; Gerona RR
    Drug Test Anal; 2019 Feb; 11(2):279-291. PubMed ID: 30151911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defining Steric Requirements at CB
    Markham J; Sparkes E; Boyd R; Chen S; Manning JJ; Finlay D; Lai F; McGregor E; Maloney CJ; Gerona RR; Connor M; McGregor IS; Hibbs DE; Glass M; Kevin RC; Banister SD
    ACS Chem Neurosci; 2022 Apr; 13(8):1281-1295. PubMed ID: 35404067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthetic Cannabinoid Receptor Agonists Detection Using Fluorescence Spectral Fingerprinting.
    May B; Naqi HA; Tipping M; Scott J; Husbands SM; Blagbrough IS; Pudney CR
    Anal Chem; 2019 Oct; 91(20):12971-12979. PubMed ID: 31580647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.